BACKGROUND AND PURPOSE: Dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channel causes the genetic disease cystic fibrosis (CF). Towards the development of transformational drug therapies for CF, we investigated the channel function and action of CFTR potentiators on A561E, a CF mutation found frequently in Portugal. Like the most common CF mutation F508del, A561E causes a temperature-sensitive folding defect that prevents CFTR delivery to the cell membrane and is associated with severe disease. EXPERIMENTAL APPROACH: Using baby hamster kidney cells expressing recombinant CFTR, we investigated CFTR expression by cell surface biotinylation, and function and pharmacology with the iodide efflux and patch-clamp techniques. KEY RESULTS: Low temperature incubation delivered a small proportion of A561E-CFTR protein to the cell surface. Like F508del-CFTR, low temperature-rescued A561E-CFTR exhibited a severe gating defect characterized by brief channel openings separated by prolonged channel closures. A561E-CFTR also exhibited thermoinstability, losing function more quickly than F508del-CFTR in cell-free membrane patches and intact cells. Using the iodide efflux assay, CFTR potentiators, including genistein and the clinically approved small-molecule ivacaftor, partially restored function to A561E-CFTR. Interestingly, ivacaftor restored wild-type levels of channel activity (as measured by open probability) to single A561E- and F508del-CFTR Cl(-) channels. However, it accentuated the thermoinstability of both mutants in cell-free membrane patches. CONCLUSIONS AND IMPLICATIONS: Like F508del-CFTR, A561E-CFTR perturbs protein processing, thermostability and channel gating. CFTR potentiators partially restore channel function to low temperature-rescued A561E-CFTR. Transformational drug therapy for A561E-CFTR is likely to require CFTR correctors, CFTR potentiators and special attention to thermostability.
BACKGROUND AND PURPOSE: Dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channel causes the genetic disease cystic fibrosis (CF). Towards the development of transformational drug therapies for CF, we investigated the channel function and action of CFTR potentiators on A561E, a CF mutation found frequently in Portugal. Like the most common CF mutation F508del, A561E causes a temperature-sensitive folding defect that prevents CFTR delivery to the cell membrane and is associated with severe disease. EXPERIMENTAL APPROACH: Using baby hamster kidney cells expressing recombinant CFTR, we investigated CFTR expression by cell surface biotinylation, and function and pharmacology with the iodide efflux and patch-clamp techniques. KEY RESULTS: Low temperature incubation delivered a small proportion of A561E-CFTR protein to the cell surface. Like F508del-CFTR, low temperature-rescued A561E-CFTR exhibited a severe gating defect characterized by brief channel openings separated by prolonged channel closures. A561E-CFTR also exhibited thermoinstability, losing function more quickly than F508del-CFTR in cell-free membrane patches and intact cells. Using the iodide efflux assay, CFTR potentiators, including genistein and the clinically approved small-molecule ivacaftor, partially restored function to A561E-CFTR. Interestingly, ivacaftor restored wild-type levels of channel activity (as measured by open probability) to single A561E- and F508del-CFTR Cl(-) channels. However, it accentuated the thermoinstability of both mutants in cell-free membrane patches. CONCLUSIONS AND IMPLICATIONS: Like F508del-CFTR, A561E-CFTR perturbs protein processing, thermostability and channel gating. CFTR potentiators partially restore channel function to low temperature-rescued A561E-CFTR. Transformational drug therapy for A561E-CFTR is likely to require CFTR correctors, CFTR potentiators and special attention to thermostability.
Authors: Liying Cui; Luba Aleksandrov; Xiu-Bao Chang; Yue-Xian Hou; Lihua He; Tamas Hegedus; Martina Gentzsch; Andrei Aleksandrov; William E Balch; John R Riordan Journal: J Mol Biol Date: 2006-11-10 Impact factor: 5.469
Authors: Mónica Roxo-Rosa; Zhe Xu; André Schmidt; Mário Neto; Zhiwei Cai; Cláudio M Soares; David N Sheppard; Margarida D Amaral Journal: Proc Natl Acad Sci U S A Date: 2006-11-10 Impact factor: 11.205
Authors: Adrian W R Serohijos; Tamás Hegedus; Andrei A Aleksandrov; Lihua He; Liying Cui; Nikolay V Dokholyan; John R Riordan Journal: Proc Natl Acad Sci U S A Date: 2008-02-27 Impact factor: 11.205
Authors: Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard Journal: Br J Pharmacol Date: 2018-02-22 Impact factor: 8.739
Authors: Nikhil T Awatade; Inna Uliyakina; Carlos M Farinha; Luka A Clarke; Karina Mendes; Amparo Solé; Juan Pastor; Maria Margarida Ramos; Margarida D Amaral Journal: EBioMedicine Date: 2014-12-17 Impact factor: 8.143
Authors: Xin Meng; Yiting Wang; Xiaomeng Wang; Joe A Wrennall; Tracy L Rimington; Hongyu Li; Zhiwei Cai; Robert C Ford; David N Sheppard Journal: J Biol Chem Date: 2017-01-13 Impact factor: 5.157
Authors: Gudio Veit; Radu G Avramescu; Annette N Chiang; Scott A Houck; Zhiwei Cai; Kathryn W Peters; Jeong S Hong; Harvey B Pollard; William B Guggino; William E Balch; William R Skach; Garry R Cutting; Raymond A Frizzell; David N Sheppard; Douglas M Cyr; Eric J Sorscher; Jeffrey L Brodsky; Gergely L Lukacs Journal: Mol Biol Cell Date: 2016-02-01 Impact factor: 4.138
Authors: Miklos Bagdany; Guido Veit; Ryosuke Fukuda; Radu G Avramescu; Tsukasa Okiyoneda; Imad Baaklini; Jay Singh; Guy Sovak; Haijin Xu; Pirjo M Apaja; Sara Sattin; Lenore K Beitel; Ariel Roldan; Giorgio Colombo; William Balch; Jason C Young; Gergely L Lukacs Journal: Nat Commun Date: 2017-08-30 Impact factor: 14.919